JP2016212116A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016212116A5 JP2016212116A5 JP2016153332A JP2016153332A JP2016212116A5 JP 2016212116 A5 JP2016212116 A5 JP 2016212116A5 JP 2016153332 A JP2016153332 A JP 2016153332A JP 2016153332 A JP2016153332 A JP 2016153332A JP 2016212116 A5 JP2016212116 A5 JP 2016212116A5
- Authority
- JP
- Japan
- Prior art keywords
- prognosis
- survival
- diagnosis
- subject
- biomarkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 12
- 230000004083 survival effect Effects 0.000 claims 7
- 238000004393 prognosis Methods 0.000 claims 5
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 4
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims 4
- 102100023123 Mucin-16 Human genes 0.000 claims 4
- 239000000090 biomarker Substances 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 4
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 238000011256 aggressive treatment Methods 0.000 claims 2
- 238000010837 poor prognosis Methods 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100036154 Platelet basic protein Human genes 0.000 claims 1
- 108010071690 Prealbumin Proteins 0.000 claims 1
- 102000009190 Transthyretin Human genes 0.000 claims 1
- 108010035886 connective tissue-activating peptide Proteins 0.000 claims 1
- 102000018511 hepcidin Human genes 0.000 claims 1
- 229940066919 hepcidin Drugs 0.000 claims 1
- 108060003558 hepcidin Proteins 0.000 claims 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40604410P | 2010-10-22 | 2010-10-22 | |
| US61/406,044 | 2010-10-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535113A Division JP2013541716A (ja) | 2010-10-22 | 2011-10-21 | 卵巣癌の患者における予後予測バイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016212116A JP2016212116A (ja) | 2016-12-15 |
| JP2016212116A5 true JP2016212116A5 (enExample) | 2017-01-26 |
Family
ID=45975910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535113A Pending JP2013541716A (ja) | 2010-10-22 | 2011-10-21 | 卵巣癌の患者における予後予測バイオマーカー |
| JP2016153332A Pending JP2016212116A (ja) | 2010-10-22 | 2016-08-04 | 卵巣癌の患者における予後予測バイオマーカー |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535113A Pending JP2013541716A (ja) | 2010-10-22 | 2011-10-21 | 卵巣癌の患者における予後予測バイオマーカー |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2630498A4 (enExample) |
| JP (2) | JP2013541716A (enExample) |
| AU (1) | AU2011316844A1 (enExample) |
| CA (1) | CA2818593A1 (enExample) |
| WO (1) | WO2012054824A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3210220A1 (en) * | 2013-05-10 | 2014-11-13 | Johns Hopkins University | Compositions for ovarian cancer assessment having improved specificity |
| WO2015163424A1 (ja) | 2014-04-23 | 2015-10-29 | 株式会社ニチレイバイオサイエンス | 標的マーカー検出用組合せ物 |
| EP3435379A1 (en) * | 2017-07-27 | 2019-01-30 | Roche Diagnostics GmbH | Augmenting measurement values of biological samples |
| WO2019088709A2 (ko) * | 2017-10-31 | 2019-05-09 | 국립암센터 | Nc886 유전자를 이용한 난소암 예후 예측을 위한 정보제공방법 |
| JP7272627B2 (ja) * | 2019-01-24 | 2023-05-12 | 公立大学法人和歌山県立医科大学 | 卵巣腫瘍の評価用バイオマーカー |
| EP3980764A4 (en) * | 2019-06-06 | 2023-07-05 | Icahn School of Medicine at Mount Sinai | SYSTEMS AND METHODS FOR DIAGNOSIS OF BIOLOGICAL DISEASES RELATED TO PERIODIC VARIATIONS OF METAL METABOLISM |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1540010B8 (en) * | 2002-08-06 | 2010-07-14 | The Johns Hopkins University | Use of biomarkers for detecting ovarian cancer |
| DK2199801T3 (da) * | 2004-07-14 | 2013-08-05 | Univ California | Biomarkører til tidlig påvisning af ovariecancer |
| NZ560976A (en) * | 2005-03-11 | 2011-06-30 | Univ Johns Hopkins | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| EP2993474B1 (en) * | 2005-06-24 | 2019-06-12 | Vermillion, Inc. | Biomarkers for ovarian cancer: beta-2 microglobulin |
| WO2008060376A2 (en) * | 2006-10-04 | 2008-05-22 | The Johns Hopkins University | Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer |
| WO2008048508A2 (en) * | 2006-10-13 | 2008-04-24 | Vermillion, Inc. | Prognostic biomarkers in patients with ovarian cancer |
| EP2637020A3 (en) * | 2007-06-29 | 2014-01-08 | Correlogic Systems Inc. | Predictive markers for ovarian cancer |
| JP5391400B2 (ja) * | 2007-10-01 | 2014-01-15 | 公益財団法人ヒューマンサイエンス振興財団 | α−アクチニン−４遺伝子のコピー数または発現レベルを指標とした膵癌の検出を補助する方法および診断のためのキット |
| WO2009058331A2 (en) * | 2007-10-29 | 2009-05-07 | Vermilllion, Inc. | Biomarkers for the detection of early stage ovarian cancer |
| EP2396657B1 (en) * | 2009-02-16 | 2013-11-13 | Atlas Antibodies AB | Rbm3 as a marker for malignant melanoma prognosis |
-
2011
- 2011-10-21 EP EP11835211.1A patent/EP2630498A4/en not_active Ceased
- 2011-10-21 CA CA2818593A patent/CA2818593A1/en not_active Abandoned
- 2011-10-21 JP JP2013535113A patent/JP2013541716A/ja active Pending
- 2011-10-21 WO PCT/US2011/057271 patent/WO2012054824A2/en not_active Ceased
- 2011-10-21 AU AU2011316844A patent/AU2011316844A1/en not_active Abandoned
-
2016
- 2016-08-04 JP JP2016153332A patent/JP2016212116A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016212116A5 (enExample) | ||
| Iseki et al. | Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer | |
| Hu et al. | The plasma lncRNA acting as fingerprint in non-small-cell lung cancer | |
| Gertler et al. | Prevalence and topography of lymph node metastases in early esophageal and gastric cancer | |
| Xu et al. | A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma | |
| Shafqat et al. | Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis | |
| Zhou et al. | Prognostic value of PLR in various cancers: a meta-analysis | |
| Liu et al. | The RML of lymph node metastasis was superior to the LODDS for evaluating the prognosis of gastric cancer | |
| Liu et al. | Superior mesenteric artery margin of posttherapy pancreaticoduodenectomy and prognosis in patients with pancreatic ductal adenocarcinoma | |
| Varadhachary et al. | Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset | |
| Wang et al. | Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma | |
| Zhou et al. | Pretreatment albumin/globulin ratio predicts the prognosis for small-cell lung cancer | |
| Chen et al. | A nomogram to predict prognostic value of red cell distribution width in patients with esophageal cancer | |
| Akagi et al. | Lymph node evaluation and survival in colorectal cancer: review of population-based, prospective studies | |
| Yang et al. | Prognostic value of visceral pleural invasion in non‐small cell lung cancer: A propensity score matching study based on the SEER registry | |
| WO2007035676A3 (en) | Methods and materials for identifying the origin of a carcinoma of unknown primary origin | |
| Jiang et al. | The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer | |
| NZ629074A (en) | Biomarkers for gastric cancer and uses thereof | |
| Lee et al. | Different lymph node staging systems in patients with gastric cancer from Korean: What is the best prognostic assessment tool? | |
| Chu et al. | Impact on survival of the number of lymph nodes resected in patients with lymph node-negative gastric cancer | |
| Zhang et al. | The prognostic value of preoperative inflammation-based prognostic scores and nutritional status for overall survival in resected patients with nonmetastatic Siewert type II/III adenocarcinoma of esophagogastric junction | |
| Ke et al. | Prognostic value of the lymph node ratio in stage III gastric cancer patients undergoing radical resection | |
| Liska et al. | Evaluation of tumor markers and their impact on prognosis in gallbladder, bile duct and cholangiocellular carcinomas–a pilot study | |
| Wang et al. | Prognostic role of C-reactive protein to albumin ratio in colorectal cancer: A meta analysis | |
| Xu et al. | Does tumor size improve the accuracy of prognostic predictions in node-negative gastric cancer (pT1-4aN0M0 stage)? |